Payment overview · 2025
General Payments
$221.65
6 reported records · 5 companies
Healthcare provider profile · identity verified
Brett Twente, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MILWAUKEE, WI · NPI 1194784629
Verified facts
What the public records show
CMS Open Payments records show Brett Twente, MD received $221.65 in general payments during 2025 across 6 reported records.
AstraZeneca Pharmaceuticals LP accounted for 54.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $121.11 | 54.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.54 | 16.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.28 | 11.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.94 | 10.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.78 | 7.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $221.65 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $121.11 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $35.54 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $25.28 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $25.28 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1230 | 304 |
| Amlodipine Besylate | Amlodipine Besylate | 779 | 195 |
| Losartan Potassium | Losartan Potassium | 640 | 163 |
| Lisinopril | Lisinopril | 423 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 421 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 354 | 86 |
| Omeprazole | Omeprazole | 338 | 80 |
| Metformin Hcl | Metformin Hcl | 305 | 75 |
| Gabapentin | Gabapentin | 298 | 62 |
| Eliquis | Apixaban | 249 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 249 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 235 | 54 |
| Sertraline Hcl | Sertraline Hcl | 231 | 64 |
| Carvedilol | Carvedilol | 219 | 52 |
| Trulicity | Dulaglutide | 213 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 52 |
| Metformin Hcl Er | Metformin Hcl | 190 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 189 | 67 |
| Furosemide | Furosemide | 185 | 46 |
| Allopurinol | Allopurinol | 183 | 44 |
| Mirtazapine | Mirtazapine | 168 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 166 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 159 | 52 |
| Potassium Chloride | Potassium Chloride | 147 | 37 |
| Trazodone Hcl | Trazodone Hcl | 139 | 32 |
| Tramadol Hcl | Tramadol Hcl | 134 | 25 |
| Alprazolam | Alprazolam | 133 | 22 |
| Jardiance | Empagliflozin | 125 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 116 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 30 |
| Warfarin Sodium | Warfarin Sodium | 112 | 12 |
| Spironolactone | Spironolactone | 106 | 34 |
| Lorazepam | Lorazepam | 95 | 21 |
| Finasteride | Finasteride | 92 | 20 |
| Simvastatin | Simvastatin | 89 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 17 |
| Alendronate Sodium | Alendronate Sodium | 87 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 20 |
| Xarelto | Rivaroxaban | 81 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | 15 |
| Pregabalin | Pregabalin | 59 | 14 |
| Clonazepam | Clonazepam | 57 | 11 |
| Ezetimibe | Ezetimibe | 56 | 17 |
| Famotidine | Famotidine | 55 | 14 |
| Glipizide Er | Glipizide | 55 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 12 |
| Montelukast Sodium | Montelukast Sodium | 53 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 19 |
| Spiriva Handihaler | Tiotropium Bromide | 49 | suppressed |
| Chlorthalidone | Chlorthalidone | 47 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 18 |
| Donepezil Hcl | Donepezil Hcl | 46 | 13 |
| Meloxicam | Meloxicam | 44 | 11 |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 12 |
| Baclofen | Baclofen | 38 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 38 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | suppressed |
| Ozempic | Semaglutide | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 34 | 23 |
| Valsartan | Valsartan | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 30 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Clotrimazole | Clotrimazole | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 12 |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Prednisone | Prednisone | 18 | 15 |
| Lidocaine | Lidocaine | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 15 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Colchicine | Colchicine | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $221.65 · 6 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, ENTRESTO, Kerendia, LEQVIO, Ozempic, SHINGRIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error